Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Bivalent BNT162b2 in Healthy Infants
NCT05630352Phase 1Withdrawn
- Sponsor
- BioNTech SE
- Start
- Jan 2025
- Primary completion
- Jul 2026
- Modality
- Vaccines & Immunotherapeutics, Lipid-based Nanoparticles, mRNA Therapeutics
01
Overview
Phase 1, randomised, open-label trial of Comirnaty Bivalent Original/Omicron BA.4/BA.5 in coronavirus disease 2019 (COVID-19) (4 arms), sponsored by BioNTech SE. Primary endpoints: Percentage of participants reporting local reactions, Percentage of participants reporting systemic events and 2 more. Planned start Jan 2025; status: withdrawn.
02
Drugs
Comirnaty Bivalent Original/Omicron BA.4/BA.5
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05630352.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05630352.